FDA Reviewing Tofersen for SOD1-ALS; Decision Expected in January
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Biogen for approval of the…
Articles by Marisa Wexler, MS
Experimental Antibody GNK301 Shows Promise in Treating ALS
A viral protein called HERV-K ENV is often detectable in the fluid around the brains of people with amyotrophic…
Inflammatory Immune Cells May Be Biomarker for Juvenile Type of ALS
Amyotrophic lateral sclerosis (ALS) type 4 — a juvenile and slowly progressive form of the neurological disease, called ALS4…
Imaging Analysis Platform May Help Diagnose ALS
An imaging analysis platform that examines the brain’s white matter in MRI scans could help to diagnose amyotrophic lateral…
Radicava’s Real-world Safety Profile Matches Clinical Trial Data: Study
Using the approved treatment Radicava (edaravone) in a real-world setting resulted in a similar safety profile as that reported…
Finding TDP-43 Clumps in Muscle Biopsies May Speed Diagnosis
Doing a muscle biopsy to look for abnormal clumps of the TDP-43 protein in the nerve fibers of muscle tissue…
ILB Safe, Shows Potential to Slow ALS Progression in Small Phase 2 Trial
TikoMed reported that ILB, its investigational therapy to protect nerve cells in amyotrophic lateral sclerosis (ALS), was well-tolerated by patients, and…
Radicava ORS Shows Safety, Tolerability Over Nearly Year of Use
Radicava ORS, an oral formulation of edaravone recently approved to treat amyotrophic lateral sclerosis (ALS) in the U.S.,…
Albrioza, Oral ALS Therapy Known as AMX0035, Approved in Canada
Albrioza, formerly called AMX0035, has been given conditional approval by Health Canada for the treatment of amyotrophic lateral…
CNM-Au8 Extends Survival, RESCUE-ALS Study Suggests
Treatment with the experimental gold nanocrystal therapy CNM-Au8 decreased the risk of mortality by 64% among people with early…